id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
DEA-2023-0028-2951,DEA,DEA-2023-0028,Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients,Rule,,2025-03-24T04:00:00Z,2025,3,2025-03-24T04:00:00Z,,2025-06-03T00:09:09Z,2025-05007,0,0,0900006486a29032
DEA-2023-0028-2918,DEA,DEA-2023-0028,Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients,Rule,,2025-02-19T05:00:00Z,2025,2,2025-02-19T05:00:00Z,2025-03-01T04:59:59Z,2025-03-01T23:55:45Z,2025-02793,0,0,0900006486971375
DEA-2023-0028-2917,DEA,DEA-2023-0028,Expansion of Buprenorphine Treatment via Telemedicine Encounter,Rule,,2025-01-17T05:00:00Z,2025,1,2025-01-17T05:00:00Z,,2025-01-21T13:53:50Z,2025-01049,0,0,09000064868e2eb2
DEA-2023-0028-0001,DEA,DEA-2023-0028,Expansion of Induction of Buprenorphine via Telemedicine Encounter,Proposed Rule,,2023-03-01T05:00:00Z,2023,3,2023-03-01T05:00:00Z,2023-04-01T03:59:59Z,2023-04-01T23:39:12Z,2023-04217,0,0,09000064857323db